Immunohistochemistry (IHC) is an indispensable tool for research laboratories by providing spatial context and phenotypic data. Multiplex immunohistochemistry technologies are in the early stages of disrupting legacy assays and revealing previously unknown relationships in all types of tissues.
Understanding how to apply and utilize multiplexing techniques, including identifying the right antibodies to use, is the first step for the development of novel assays and interpretation of the data. Enabling a simple and relatable workflow for these assays will empower researchers and encourage adoption of this important technique.
Register for this webinar to understand the advantages of using fluorescence versus brightfield IHC assays and learn how to utilize the data produced from multiplex immunohistochemistry assays.
Speaker
Matt Levin, BSc, R&D Manager, Leica Biosystems
Matt Levin has dedicated his professional career to answer the resonating whys in the field of protein chemistry and immunology. He is currently an R&D Manager at Cell IDx, a Leica Biosystems Company, and his team are motivated to share their laboratory results with the world to not only improve the quality of people’s lives, but also leave the world as a better place. Over the past decade, Matt and his team have dedicated their efforts to create an improved multiplex immunohistochemistry assay.
Message PresenterWho Should Attend?
This webinar will appeal to scientists and cancer researchers interested in advancing translational science, particularly those using chromogenic and fluorescent multiplexing technologies from pharmaceutical and biotech companies and universities:
- Research Scientist/Associate
- Principal Investigator
- Scientist/Senior Scientist
- Pathologist
- Directors of R&D or Digital Imaging
- Lab Manager
- Research and Development Coordinator
- Managers in Pharmaceutical and Biotechnology Companies
What You Will Learn
After the webinar, attendees will be able to:
- Identify appropriate antibodies to use in a multiplex immunohistochemistry (IHC) assay
- Understand advantages of using fluorescence versus brightfield IHC Assays
- Learn how to utilize the data produced from multiplexed IHC Assays
Xtalks Partner
Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Leica Biosystems is headquartered in Germany and operates in over 100 countries.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account